All In Biotech

Drug Trial Radar · NCT02517385

Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases

Multicenter Prospective Uncontrolled Non-comparative Open Interventional Clinical Study of Phase III for Assessment of the Safety and Effectiveness of Using the Drug Phosphatidylcholine Paste 600 mg in Patients With Acute and Chronic Liver Diseases and Clinical Symptoms of Dysfunction of the Gastrointestinal Tract During 12-week Therapy Course

Last checked: Nov 20, 2026Latest source record: Jul 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Aug 2015

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 66 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess safety of Phosphatidylcholine paste 600 mg (ESSENTIALE® paste) oral 3 times a day for 12 weeks in patients with gastrointestinal symptoms in acute and chronic liver diseases. Secondary Objectives: To assess effectiveness on symptomatic improvement in patients with gastrointestinal symptoms in acute and chronic liver diseases. To monitor compliance.

Conditions

  • Hepatic and Hepatobiliary Disorders

Interventions

  • PhosphatidylcholineDrug

    Pharmaceutical form:Paste Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency (number) of adverse events (AEs) related to the investigational drugTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.